PMID- 36303860
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240210
IS  - 2296-875X (Print)
IS  - 2296-875X (Electronic)
IS  - 2296-875X (Linking)
VI  - 9
DP  - 2022
TI  - Quality of life reporting in the management of posterior fossa tumours: A 
      systematic review.
PG  - 970889
LID - 10.3389/fsurg.2022.970889 [doi]
LID - 970889
AB  - INTRODUCTION: Survival amongst posterior fossa tumour (PFT) patients is 
      improving. Clinical endpoints such as overall survival fail to depict QoL. There 
      is yet to be a review of current QoL instruments used for adult PFTs. Aim of this 
      review is to outline the QoL reporting in the management of PFTs and measure 
      participation level. METHODS: This systematic review was conducted in accordance 
      with Preferred Reporting Items for Systematic Reviews and Meta-Analysis. A search 
      strategy to identify adult patients with PFTs who took part in QoL metrics was 
      conducted. Observational and experimental studies published from 1990 to date 
      were included. Studies with a sample size less than 10 and performance measures 
      such as Karnofsky Performance Status were not considered. RESULTS: A total of 116 
      studies were included in the final analysis. Vestibular schwannomas were the most 
      common tumour pathology (n = 23,886, 92.6%) followed by pilocytic astrocytomas 
      (n = 657, 2.5%) and meningiomas (n = 437, 1.7%) Twenty-five different QoL 
      measures were used in the study pool. SF-36 was the most common (n = 55, 17 
      47.4%) QoL metric in the whole study pool, followed by the Penn Acoustic Neuroma 
      QoL scale (n = 24, 20.7%) and Dizziness Handicap Inventory (n = 16, 13.8%). 
      Seventy-two studies reported less-than 100% participation in QoL evaluation. The 
      commonest reason for non-participation was a lack of response (n = 1,718, 60.8%), 
      incomplete questionnaires (n = 268, 9.4%) and cognitive dysfunction (n = 258, 
      9.1%). CONCLUSION: Informed clinical decision-making in PFT patients requires the 
      development of specific QoL outcomes. Core outcome sets, and minimal clinically 
      important differences (MCID) are essential for these metrics to show clinically 
      significant improvements in patient QoL.
CI  - (c) 2022 Adegboyega, Jordan, Kawka, Chisvo, Toescu and Hill.
FAU - Adegboyega, Gideon
AU  - Adegboyega G
AD  - Barts and the London School of Medicine and Dentistry, Queen Mary University of 
      London, London, United Kingdom.
FAU - Jordan, Chloe
AU  - Jordan C
AD  - Barts and the London School of Medicine and Dentistry, Queen Mary University of 
      London, London, United Kingdom.
FAU - Kawka, Michal
AU  - Kawka M
AD  - Imperial College London School of Medicine, London, United Kingdom.
FAU - Chisvo, Nathan
AU  - Chisvo N
AD  - Barts and the London School of Medicine and Dentistry, Queen Mary University of 
      London, London, United Kingdom.
FAU - Toescu, Sebastian M
AU  - Toescu SM
AD  - Department of Neurosurgery, Royal London Hospital, London, United Kingdom.
FAU - Hill, Ciaran
AU  - Hill C
AD  - Department of Neurosurgery, The National Hospital for Neurology and Neurosurgery, 
      London, United Kingdom.
AD  - University College London Cancer Institute, London, United Kingdom.
LA  - eng
GR  - 29787/CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20220929
PL  - Switzerland
TA  - Front Surg
JT  - Frontiers in surgery
JID - 101645127
PMC - PMC9594859
OTO - NOTNLM
OT  - astrocytoma
OT  - brain tumour
OT  - medulloblastoma
OT  - meningioma
OT  - quality of life
OT  - vestibular schwannoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/29 06:00
MHDA- 2022/10/29 06:01
PMCR- 2022/09/29
CRDT- 2022/10/28 02:39
PHST- 2022/06/16 00:00 [received]
PHST- 2022/08/23 00:00 [accepted]
PHST- 2022/10/28 02:39 [entrez]
PHST- 2022/10/29 06:00 [pubmed]
PHST- 2022/10/29 06:01 [medline]
PHST- 2022/09/29 00:00 [pmc-release]
AID - 10.3389/fsurg.2022.970889 [doi]
PST - epublish
SO  - Front Surg. 2022 Sep 29;9:970889. doi: 10.3389/fsurg.2022.970889. eCollection 
      2022.